Optimizing Dosimetry Imaging In High-Dose Radioimmunotherapy Using The Novel, Anti-Cd45 Re-Induction And Targeted Conditioning Agent Iodine (I-131) Apamistamab [Iomab-B] In Patients 55 Years Or Olderwith Active, Relapsed Or Refractory Acute Myeloid Leukemia (Sie Phase Iii Trial)